• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Which Thrombophilias in Pregnancy Warrant Thromboprophylaxis? 

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Thrombophilias are a known risk factor for venous thromboembolism (VTE) in pregnancy
  • Pregnancy increases the risk of VTE in pregnancy approximately five to sixfold
  • Data is limited on absolute risk of pregnancy-associated VTE in women with thrombophilias and there are no meta-analyses
  • Croles et al. (BMJ, 2017) sought to establish evidence that could be used to update guidelines for prevention of VTEs in pregnant women with heritable thrombophilias

METHODS:

  • Systematic Review and meta-analysis
  • Included studies with information on specific inherited thrombophilias
    • Antithrombin deficiency
    • Protein C deficiency
    • Protein S deficiency
    • Factor V Leiden mutation (heterozygous or homozygous)
    • Prothrombin G20210A mutation (heterozygous or homozygous)
    • Compound heterozygous factor V Leiden and prothrombin G20210A mutation
  • VTE was considered established if it was confirmed by objective means, or when the patient had received a full course of a full dose anticoagulant treatment without objective testing
  • Studies were classified as family and non-family studies due to increased risk based on family history
    • Non-family cohort studies rarely included data on women with high risk thrombophilias

RESULTS:

  • 36 studies were included in the systematic review (12 case-control; 24 cohort studies)
    • 41,297 pregnancies included
  • All thrombophilias increased the risk for pregnancy-associated VTE (probabilities ≥91%)
  • Thrombophilias with high absolute risks included the following (absolute risk, using 95% credible interval range)
    • Antithrombin deficiency
      • Antepartum: 7.3% (1.8% to 15.6%)
      • Postpartum: 11.1 (3.7% to 21.0%)
    • Protein C deficiency
      • Antepartum: 3.2% (0.6% to 8.2%)
      • Postpartum: 5.4% (0.9% to 13.8%)
    • Protein S deficiency
      • Antepartum: 0.9% (0.0% to 3.7%)
      • Postpartum: 4.2% (0.7% to 9.4%)
    • Homozygous factor V Leiden
      • Antepartum: 2.8% (0.0% to 8.6%)
      • Post partum: 2.8% (0.0% to 8.8%)
    • Absolute combined antepartum and postpartum risks for women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutations, or compound heterozygous factor V Leiden and prothrombin G20210A mutations were all below 3% (cut-off for thromboprophylaxis used in some guidelines)

CONCLUSION:

  • Based on 3% risk cut-offs, authors draw the following conclusions for antepartum prophylaxis and prophylaxis up to six weeks postpartum for women with no previous VTE
    • Suggest prophylaxis for women with antithrombin and protein C deficiency if they have a positive family history.
    • Consider prophylaxis for women with homozygous factor V Leiden mutations for women with a family history and additional risk factors for VTE
    • Suggest prophylaxis for women with protein S deficiency and a positive family only in postpartum
    • Cannot give recommendations for homozygous prothrombin G20210A mutation due to lack of cohort data
  • In contrast, women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation should generally not receive thrombosis prophylaxis on the basis of thrombophilia and family history alone

Learn More – Primary Sources:

Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis

image_pdfFavoriteLoadingFavorite

Related Terms:
  • Glossary Term: Systematic review
  • Glossary Term: credible interval
  • Glossary Term: Meta-analysis
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

How Common is Venous Thromboembolism During Neoadjuvant Treatment for Ovarian Cancer?
When to Stop Anticoagulation Following a DVT or Pulmonary Embolus?
Abnormal Vaginal Bleeding and Oral Anticoagulants for DVT – Results from the AMPLIFY trial

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site